ATRACTIB

OFFICIAL TITLE: PHASE II CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF FIRST LINE ATEZOLIZUMAB IN COMBINATION WITH PACLITAXEL AND BEVACIZUMAB (AVASTIN®) IN PATIENTS WITH ADVANCED OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER 

PROJECT DETAILS

THIS IS A MULTICENTRE, OPEN-LABEL, SINGLE-ARM, PHASE II CLINICAL TRIAL. MEN AND WOMEN AGE ≥ 18 YEARS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER (TNBC) THAT IS NOT AMENABLE TO RESECTION WITH CURATIVE INTENT. PATIENTS IN THIS SINGLE-ARM STUDY (N=100) WILL RECEIVE TREATMENT (INTRAVENOUS INFUSION) WITH ATEZOLIZUMAB IN COMBINATION WITH PACLITAXEL AND BEVACIZUMAB (AVASTIN®).

 

THE MAIN OBJECTIVE IS TO EVALUATE THE EFFICACY –IN TERMS OF PROGRESSION-FREE SURVIVAL (PFS)– OF FIRST LINE ATEZOLIZUMAB IN COMBINATION WITH PACLITAXEL AND BEVACIZUMAB (AVASTIN®) IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC TNBC.

ATRACTIB AT CLINICALTRIALS.GOV

TUMOR TYPE

PHASE

Breast

II

100

45

Spain, Italy, Portugal, France, Germany and UK

N

SITES

COUNTRY

STATUS

Start up

ATRACTIB SITES

SPAIN

Instituto Valenciano de Oncología (IVO)

SPAIN

Hospital Universitari Vall D'Hebron

SPAIN

Hospital Clinic

SPAIN

Complejo Asistencial de Avila

SPAIN

Hospital Universitario Reina Sofía

SPAIN

Hospital Universitario Virgen de la Victoria

SPAIN

Hospital Clinico Universitario Santiago de Compostela

SPAIN

Centro oncologico de Galicia

SPAIN

Hospital Universitario Doce de Octubre

SPAIN

Hospital Clinico San Carlos